tirzepatide cv outcomes trial cardiovascular results july 2025 Demonstrates Cardioprotective Effects in SURPASS-CVOT 🚨 Breaking News: Real-World Data – Risk of major adverse cardiovascular

Thyroid function should be checked at baseline and monitored during treatment

After reading about the triple agonist mechanism and seeing the trial data, I decided to give it a try

Hurthle cell cancer Hurthle cell thyroid carcinoma accounts for Factors like age, tumor size at diagnosis, cancer stage at diagnosis, and sex may affect the outlook for people with Hurthle cell cancer

This is particularly true if the skin is still healing and more susceptible to pigmentation changes.3

Brotman, S

For most people taking GLP-1-based therapies including retatrutide gastrointestinal symptoms tend to be most pronounced during the early weeks of treatment and during periods of dose escalation